Retractable Technologies INC 8-K filings

Retractable Technologies, Inc. announced the declaration of dividends for its Series II and Series III Class B Convertible Preferred Stock, totaling $57,611.25 for the second quarter of 2026.

Retractable Technologies reports a $7.2 million net sales figure and a $6.2 million operating loss for the first quarter of 2026.

Retractable Technologies, Inc. reported the results of its Annual Meeting of Shareholders held on May 8, 2026, where all nominated directors were elected.

Retractable Technologies, Inc. announced a 15.8% increase in 2025 revenues to $38.3 million, alongside a declared dividend for preferred shareholders.

Retractable Technologies, Inc. announced dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders.

Retractable Technologies, Inc. announced its third quarter and year-to-date financial results, alongside receiving an Innovative Technology designation from Vizient for its EasyPoint Blood Collection Tube Holder with Needle.

Retractable Technologies, Inc. announced the declaration of dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders.

Retractable Technologies, Inc. reported increased net sales for Q2 and H1 2025, but faced continued operating losses and significant tariff costs.

Retractable Technologies, Inc. announced a 12.4% reduction in its manufacturing workforce, aiming to save $1.6 million annually in wages and benefits, offset by $56 thousand in one-time separation payments.

Retractable Technologies, Inc. announced the declaration of dividends totaling $39,050.00 for Series II Class B and $18,561.25 for Series III Class B Convertible Preferred Stock shareholders.

Retractable Technologies, Inc. announced the appointment of Baker Tilly US, LLP as its new independent registered public accounting firm, succeeding Moss Adams LLP due to a merger.

Retractable Technologies, Inc. settles a lawsuit related to previous legal representation, receiving $1.9 million without admitting liability.

Retractable Technologies, Inc. reported higher net sales but also a larger operating loss for the first quarter of 2025, driven by increased tariffs and domestic production costs.

Retractable Technologies, Inc. (RVP) announces a 7% workforce reduction to save $1.6 million annually, while shifting focus to U.S. manufacturing amid tariff concerns.

Retractable Technologies reports a significant revenue decrease and operating loss for 2024, alongside declaring dividends for Series II and Series III Class B preferred stockholders.

Retractable Technologies has withdrawn its complaint against tariffs on imported syringes and needles from China, citing a low probability of success and focusing on domestic production enhancements.

Retractable Technologies has announced the declaration of dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders.

Retractable Technologies reported flat net sales and increased operating losses for the third quarter of 2024, impacted by decreased average selling prices and new tariffs.

Retractable Technologies is facing a significant challenge due to a newly imposed 100% tariff on Chinese imports, leading to a lawsuit and the declaration of dividends to preferred shareholders.

Retractable Technologies experienced a decrease in sales and an increase in operating losses for the second quarter of 2024, primarily due to lower domestic demand and international vaccination-related sales, while also facing potential impacts from proposed tariffs on Chinese imports.

Retractable Technologies has announced the declaration of dividends for its Series II and Series III Class B Convertible Preferred Stock shareholders.

Retractable Technologies experienced a decrease in total net sales and an increased operating loss in the first quarter of 2024, primarily due to reduced international syringe sales and the anticipation of new tariffs.

Retractable Technologies experienced a significant revenue decrease in 2023 due to reduced COVID-19 vaccination sales, while also declaring dividends for its Series II and Series III Class B preferred stock.

Retractable Technologies has announced a voluntary recall of its EasyPoint Needle lot number K220402 due to a potential detachment issue that could cause serious injury.